New Similarity Ensemble Approach software is now commercially
available, offering enhanced security, speed, and the ability to
leverage both proprietary and public scientific data.
SAN FRANCISCO--(BUSINESS WIRE)--
Pharmaceuticals Inc., a privately held platform and products
pharmaceuticals company, is pleased to announce the immediate
availability of SEAware™,
its proprietary Similarity Ensemble Approach (SEA) software, that allows
analysis and visualization tools for prediction of drug and other small
molecule activity and toxicity against biological targets. Three levels
are available directly from the SeaChange website.
“Our pharma, academic, and government partners have found SEA most
valuable in-house, where it’s fast, easy, and secure,” said Michael
Keiser, Founder and COO. “We’ve had many requests to make SEA available
and we’re excited to respond today with SEAware™. It’s a turn-key
package that has 10x the calculation speed and a new, intuitive
interface—a ‘google for drug targets.’ In the most extensive suite,
users can leverage their own proprietary data or modify available public
libraries. These advances let our clients explore what-if questions
about drug off-target effects at the press of a button.”
Nicholas Hodge, Chief Scientific Officer, pointed out that “preclinical in
vitro and in vivo testing of drug candidates against the
increasing number of biological targets remains cost-prohibitive. One of
the best uses of SEAware™ is as a predictive ‘filter’ to reduce the
testing of molecules for activity or toxicity to a manageable number of
targets. As clients become familiar with the method, and build curated
reference libraries, the predictive accuracy – already high – will
continue to improve. Over time, SEA will become the method of choice for
target, mechanism and adverse effect identification of drugs and leads.
With a preclinical opportunity cost of a million dollars a day added to
random screening costs, successful application of the method can repay
the cost of software rapidly.”
The SEAware™ software package harnesses the power of our Similarity
Ensemble Approach (SEA)
to offer unprecedented utility for predicting drug effects .
It enables exploration of new therapeutic uses for known drugs ;
mechanism of drug action ; causes of
side effects and adverse drug reactions ;
and multi-target activity and polypharmacology .